Top Industry Leaders in the Heart Failure POC and LOC Devices Market
Latest Heart Failure POC & LOC Devices Companies Update:
Abbott Laboratories Launched the i-STAT BNP Test in December 2023, offering a rapid and portable POC test for B-type natriuretic peptide (BNP), a key marker for heart failure.
Roche Diagnostics Introduced the Elecsys® proBNP 2nd Generation assay in July 2023, providing increased sensitivity and specificity for BNP testing on their laboratory analyzers.
Lumio Diagnostics Received FDA clearance for their LUMIO™ Platform in October 2023, which includes a portable system for rapid, multi-analyte testing, including biomarkers for heart failure.
Singal™ Biometrics Developing a LOC device capable of simultaneously measuring multiple heart failure biomarkers on a single chip, offering rapid and comprehensive diagnosis.
Cardiome Dx Collaborating with other companies to develop and integrate AI-powered algorithms into their heart failure POC devices, enhancing diagnostic accuracy and providing real time insights.
List of Heart Failure POC & LOC Devices Key companies in the market
-
Abbott (US)
-
F. Hoffmann-La Roche Ltd. (Switzerland)
-
Danaher (US)
-
Abaxis, Inc. (US)
-
Quidel Corporation (US)
-
Siemens Healthineers (Germany)
-
JantPharmacal Corporation (US)
-
Trinity Biotech (Ireland)
-
bioMérieux S.A (France)
-
Instrumentation Laboratory Company (US)